Yarrow Bioscience, Inc.: Janus Henderson Group Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Janus Henderson Group Ltd. amended its Schedule 13G beneficial ownership filing for Yarrow Bioscience, Inc., disclosing the change to the SEC under accession number 0001274173-26-000261. The filing updates the asset manager's reported stake in the biotech company, though the amended document did not immediately specify a revised share count or percentage. Schedule 13G amendments are typically filed when a passive investor's position crosses disclosure thresholds or otherwise changes materially. Investors will watch for the updated ownership figures to gauge Janus Henderson's current influence in Yarrow's shareholder base.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Yarrow Bioscience, Inc., Janus Henderson Group Ltd.